Resolution n°3
Action name: TB/MDR-TB
Organization(s): Global Drug Facility (GDF)

The Board of UNITAID authorizes the Executive Secretary to commit up to US$ 33,690,000 for the Global Drug Facility Project, Multi-Drug Resistant (MDR)-TB Scale-up and Acceleration of Access: 2008-2011.

Lead recipient:
The Global Drug Facility (GDF) of the Stop TB Partnership

Purpose:
To scale up MDR-TB control and to positively impact MDR-TB market dynamics to increase the affordability of second-line anti-TB drugs between 2008-2011.

Amount:
Total: US$ 33,690,000

Date of first disbursement:
July 1st, 2008

Conditions for UNITAID funding support:
GDF to provide to the reasonable satisfaction of the Secretariat and, if indicated, of the Expert Review Group, the following:
- Clarification as to how the Project intends to manage the challenges originating from the lack of a country's efficient laboratory diagnostic capability;
- For expert approval whether both Kanamycin and Capreomycin need to be budgeted for as part of one regimen and the time-line for the treatment and cost;
- A detailed M&E plan.

Signature of UNITAID legal agreement with budget

Philippe Douste-Blazy